Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.

Trial Profile

Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Methylprednisolone; Methylprednisolone; Octreotide
  • Indications Cancer metastases; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Feb 2012 Results published in the Bulletin du Cancer.
    • 13 Apr 2010 Planned end date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Actual patient number (64) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top